2013 Towards an HIV Cure Symposium
29 & 30 June 2013 | Kuala Lumpur, Malaysia

Under the auspices of the International AIDS Society, an international working group of researchers developed a Global Scientific Strategy “Towards an HIV Cure”, which was launched at a scientific symposium immediately preceding the XIX International AIDS Conference in Washington, DC in July 2012. The symposium, which received positive scientific feedback, provided a platform to present state-of-the-art basic science and clinical research on the HIV cure research priority areas defined in the strategy.

Following the publication of the Global Scientific Strategy in Nature Reviews Immunology and the success of the symposium, the IAS and the “Towards an HIV Cure” Advisory Board convened another 2-day pre-conference symposium immediately prior to the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur in June 2013.

The symposium, co-chaired by Françoise Barré-Sinoussi, IAS President, Steven Deeks, Professor of Medicine at the University of California, San Francisco (UCSF), and Sharon Lewin, Director of the Infectious Diseases Unit, Alfred Hospital, Monash University, was closely linked to the IAS 2013 conference programme.

Objectives

  • Develop knowledge on the priorities that future research must address in order to tackle HIV persistence in patients on ART.
  • Accelerate research on viral reservoirs as the way towards achieving a cure for HIV infection
  • Provide an opportunity for scientists who are working on HIV cure to share ideas, debate, and network among their peers
  • Promote increased investments in HIV/AIDS cure research
  • Provide a platform for information-sharing between scientists, clinicians, funders, media and members of civil society.

Themes of the Symposium

The symposium was structured around an opening keynote speaker, four oral abstract sessions, two roundtable discussions, a poster exhibition and a closing keynote presentation. It also include two award ceremonies; the CNIHR award programme and the IAS-ANRS Prize on HIV Cure.

Day 1

  • Oral Abstract Session 1: Cellular sensing and regulation of HIV production
  • Roundtable Discussion: Pharma collaboration and regulatory issues
  • Oral Abstract Session 2: Characterizing the reservoir in tissues and T cell subsets

Day 2

  • Oral Abstract Session 3: Kick and Kill: Novel approaches to reversing latency and immune clearance
  • Oral Abstract Session 4: Clinical interventions targeting the HIV reservoir
  • Roundtable Discussion: Ethics and patient expectations

CNIHR Award Ceremony

In collaboration with the U.S. Centers for AIDS Research and the U.S. National Institutes of Health, the IAS awards for the third time the grant programme 'Creative and Novel Ideas in HIV Research' (CNIHR). In 2013, the CNIHR grant programme supports scientists withour prior experience in HIV cure research with the aim of supporting innovative approaches with the potential of contributing to the search for an HIV cure. Eleven research grants worth up to US$150,000 per year for one to two years were awarded at IAS 2013. The initiative aims to foster cross-disciplinary research, promote novel ideas and aid in the success of investigators at an early career stage. Read more

IAS-ANRS Prize on HIV Cure

The US$2,000 IAS/ANRS Young Investigator Award is jointly funded by the IAS and the Agence Nationale de Recherche sur le sida et les hépatites virales (ANRS) to support young researchers who demonstrate innovation, originality, rationale and quality in the field of HIV/AIDS research. The 2013 Prize was awarded to Lachlan Gray, Monash University & Burnet Institute, Australia. Read more

The Symposium Programme Committee

With the support of:

 

Symposium material

  • Related documents
  • Day 1
  • Day 2
  • Poster Exhibition
  • Multimedia

Opening Session

Opening Lecture: Towards a Cure for HIV-Infected Children: Hype and Hope
Deborah Persaud, John Hopkins University School of Medicine

CNIHR Award Ceremony


Oral Abstract Session 1: Cellular sensing and regulation of HIV production

Invited Speaker: Double impact of CTIP2 on establishment and persistence of latency
Olivier Rohr, IUT Louis Pasteur, University of Strasbourg, Institut Universitaire de France, France

Presentation

OA1-1: Viral protein U (Vpu) reduces innate sensing of human immunodeficiency virus type 1 (HIV-1)-infected T cells by plasmacytoid dendritic cells (pDCs) via a BST-2 dependent process
Éric A. Cohen, Institut de recherches cliniques de Montréal, Canada

Abstract | Presentation

OA1-2: Dendritic cell-lymphocyte crosstalk stimulates HIV-1 replication and impairs host restriction factor SAMHD1 in dendritic cells
Bin Su, Inserm, France

Abstract

OA1-3: Cell-intrinsic HIV-1 immune responses in conventional dendritic cells from HIV-1 elite controllers
Xu Yu, Ragon Institute of MGH, MIT and Harvard, United States

Abstract

OA1-4 LB: Sustained high levels of circulating Galectin-9 despite viral suppression among HIV infected elite controllers
Lishomwa Ndhlovu, University of Hawaii, United States

Abstract

OA1-5 LB: Teaching new dogs new tricks: An in vitro model of autologous HIV-1 immunotherapy induces CTL from naïve precursors in subjects on ART
Kellie Smith, University of Pittsburgh, United States

Abstract | Presentation

Roundtable Discussion: Pharma collaboration and regulatory issues

Design and development considerations for immune augmentation to assist in virus eradication
Charles Nicolette, Argos Therapeutics, United States

Presentation

Pharma collaboration and regulatory issues
Guenter Kraus, Janssen, Belgium, Veronica Miller, Forum for HIV Collaborative Research, United States

Presentation

Industry Collaboration & Regulatory Issues
Bill Whittaker, National Association of People with HIV (NAPWHA), Australia

Presentation

Clinical trial risk and informed consent
Hiroyu Hatano, University of San Francisco, California, United States

Presentation

Oral Abstract Session 2: Characterizing the reservoir in tissues and T cell subsets

OA2-1: Targeting HIV-1 persistence in CD4 T memory stem cells by pharmaceutical inhibition of beta-catenin
Mathias Lichterfeld, Massachusetts General Hospital, United States

Abstract

OA2-2: Longitudinal analysis of infection frequencies and genetic make-up of intracellular HIV-1 from tissue compartments during long-term suppressive therapy
Sarah Palmer, Westmead Millennium Institute for Medical Research and University of Sydney, Australia

Abstract | Presentation

OA2-3: Identification and characterization of CD4 T cells actively transcribing HIV RNA in peripheral blood
Richard Koup, Vaccine Research Center, United States

Abstract | Presentation

OA2-4: In vivo analysis of the replication capacity and pathogenic potential of HIV primary isolates from an elite suppressor
Michael Swanson, University of North Carolina at Chapel Hill, United States

Abstract | Presentation

OA2-5 LB: BIT225, a novel inhibitor of HIV-1 release from HIV-1 reservoirs of the myeloid lineage
John Wilkinson, Biotron Limited, Australia

Abstract | Presentation

OA2-6 LB: Gag-positive reservoir cells are identified by a new technique and are susceptible to HIV-specific cytotoxic T lymphocyte
Una O’Doherty, University of Pennsylvania, United States

Abstract | Presentation

OA2-7 LB: HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC trial
James P. Williams, University of Oxford, United Kingdom

Abstract | Presentation

Oral Abstract Session 3: Kick and Kill: Novel approaches to reversing latency and immune clearance

Invited Speaker: Cyclic Panobinostat (LBH589) dosing in HIV-1 patients: Findings from the CLEAR trial
Martin Tolstrup, Aarhus University, Denmark

Presentation

OA3-1: Activation of the Wnt pathway by natural ligands or small molecule inhibitors activates latent HIV
Tokameh Mahmoudi, Erasmus Medical Centre, The Netherlands

Abstract | Presentation

OA3-2: Inducing HIV-1 in latently infected T cells with an autologous full length HIV-1 representing the majority intrapatient virus population
Eric Arts, Case Western Reserve University, United States

Abstract | Presentation

OA3-3: Destruction of the residual active HIV-1 reservoir by Env-specific immunotoxin
J. Victor Garcia, University of North Carolina at Chapel Hill, United States

Abstract | Presentation

OA3-4 LB: Entinostat is a histone deacetylase (HDAC) inhibitor selective for class 1 HDACs and activates HIV production from latently infected primary T cells
Fiona Wightman, Monash University & Burnet Institute, Australia

Abstract | Presentation

Oral Abstract Session 4: Clinical interventions targeting the HIV reservoir

Invited Speaker: Towards cure in clinical trials?
Christine Katlama, Paris 6 University Hôpital Pitié-Salpétrière, France

Presentation

OA4-1: Impact of 12-month HAART on cell-associated HIV-DNA in acute primary HIV-1 infection in the OPTIPRIM ANRS 147 trial
Antoine Cheret, Paris Descartes  Sorbonne-Paris-Cité University and Tourcoing Hospital, France

Abstract | Presentation

OA4-2: In chronically HIV-1 infected patients long-term antiretroviral therapy initiated above 500 CD4/mm3 achieves better HIV-1 reservoir depletion and T-cell restoration
Laurent Hocqueloux, CHR d’Orléans, France

Abstract | Presentati on

OA4-3 LB: Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1: A Phase-1b clinical study of a humanized monoclonal antibody KD-247 (KD-1002)
Shuzo Matsushita, Kumamoto University, Japan

Abstract | Presentation

OA4-4 LB: In depth investigation of peripheral and gut HIV-1 reservoirs, HIV-specific cellular immunity, and host microchimerism following allogeneic hematopoetic stem cell transplantation
Timothy Henrich, Brigham Women’s Hospital & Harvard Medical School, United States

Abstract

Roundtable Discussion: Ethics and patient expectations

Presentation 1: Bioethical considerations in HIV cure research
Jeremy Sugarman, John Hopkins Berman Institute of Bioethics, United States

Presentation 2:Patient expectations in HIV cure research, presently and in the future
Laurindo Garcia, B-Change, The Phillipines

Presentation 3: The role of community-based organizations/ethics and patient expectations in HIV cure research
Eric Fleutelot, Sidaction, France

Presentation 4: Selecting participants for HIV cure research: balancing ethics, patient expectations and desired outcomes
Bruno Spire, Inserm, France

Presentation 5: Participation of women in clinical studies pertinent to HIV cure
Rowena Johnston, amfAR, United States

Presentation 6: Experience from an HDACi trial: implications on ethics and patient expectations
Sharon Lewin, The Alfred Hospital, Monash University & Burnet Institute, Australia

Closing Session

Closing Lecture: The future of HIV cure research and the NIH
Carl Dieffenbach, NIAID, NIH

Presentation

IAS-ANRS HIV Cure Young Investigator Award Ceremony

A1 – HIV and SIV diversity

Positive Selection and Functional Effects of Amino Acid Substitutions in Tat exon 1 during Primary HIV-1C Infection
Raabya Rossenkhan, University of Botswana, Harvard School of Public Health & Botswana Harvard AIDS Institute, Botswana & United States


A5 - Entry (attachment, receptors and co-receptors, penetration and tropism)

HIV-1 entry and ­trans­-infection in astrocytes: implications for cure and eradication
Lachlan Gray, Monash University & Burnet Institute, Australia

Abstract

A8 - Regulation of viral gene expression and replication

Suppression of HIV-1C virus production in human PBMCs by dsRNA induced Chromatin remodeling of LTR promoter
Anand Singh, All India Institute of Medical Sciences, India

Abstract

A9 - Cellular factors necessary for HIV replication

Restriction of HIV-1 infection in dendritic cells avoids induction of IFN-α-mediated responses and reduces chemokine expression. Impact on viral escape and establishment of CD4 reservoirs
Esther Calonge, Instituto de Salud Carlos III, Spain

Abstract

Involvement of Human Topoisomerase II isoforms in the Strand transfer events of HIV-1 Reverse Transcription
Sunnam Lokeswara Balakrishna, University of Hyderabad, India

Abstract | Poster

A10 - Cellular and tissue reservoirs

Efficient infection of healthy donors´ monocyte derived macrophages by erythrocyte-associated HIV
Lucia Fazzi, Buenos Aires University, Argentina

Abstract

Erythrocyte-associated HIV in a model of HIV infection
Lucia Fazzi, Buenos Aires University, Argentina

Abstract

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments
Slim Fourati, Inserm, France

Abstract | Poster

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy
Slim Fourati, Inserm, France

Abstract | Poster

T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection
Laurence Weiss, Institut Pasteur & Université Paris Descartes, France

Abstract | Poster

A11 - Mechanisms of HIV persistence

HIV-1 resistance mutations by ultradeep pyrosequencing in proviral DNA of patients at success of a first line ART
Herve Fleury, University Hospital of Bordeaux, France

Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens
Ricardo Sobhie Diaz, Federal University of Sao Paulo, Brazil

Abstract | Poster

A13 - Strategies to target and eradicate reservoirs

Archived HIV-1 CTL Epitopes and HLA I Alleles of Patients at Success of a First Line ART: Toward a New Concept of Curative Vaccine
Herve Fleury, University Hospital of Bordeaux, France

Establishment of Macaque CD4+ T Cells and CD34+ Hematopoietic Stem Cells resistant to SIV Infection using Zinc Finger Nucleases Technology
Marie-Claire.E. Gauduin, Texas Biomedical Research Institute, United States

Abstract

Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function
Carey Hwang, Bristol-Myers Squibb, United States

Abstract

Combination of proteasome and Hsp90 inhibitors induces autophagic cell death in HIV-1-infected macrophages and CD4+ T cells: approaches to elimination of the virus reservoirs
Alexander Kabakov, Medical Radiology Research Center, Russian Federation

Abstract

Maraviroc (MVC) intensification can activate NFkB through CCR5 and the expression of its target genes in resting CD4+-T-cells in suppressed HIV-1-infected patients (Late Breaker)
Santiago Moreno, Hospital Ramón y Cajal, Spain

Abstract

Metal Nanoparticles Reduce Intracellular HIV-1 Replication and Stimulate Growth of HIV-1 Infected PBMC
Sellappa K. Prakash, Naval AIDS Research Center, India

Abstract | Poster

HIV Resistance to Dolutegravir (DTG) Simultaneously Diminishes Viral DNA Integration into Host Cells and Viral Replication Fitness: Implications for HIV Reservoirs
Mark Wainberg, McGill University, Canada

Abstract

A14 - Mucosal transmission

The intestinal microenvironment affects the susceptibility of DCs to HIV-1
Mariangela Cavarelli, San Raffaele Scientific Institute, Italy

Abstract

A18 - Innate sensors of HIV

Female genital epithelial cells from HIV-exposed seronegative commercial sex workers express a discrete cytokine/chemokines profile upon toll-like receptor activation
Nyla Dil, University of Manitoba & Public Health Agency of Canada, Canada

Abstract | Poster

A19 - Intrinsic cellular defences and restriction factors

A Population-based Matched-cohort Study on Insertion/Deletion Polymorphism of the APOBEC3B gene and Risk of HIV-1
Mayumi Imahashi, Nagoya Medical Center & Nagoya University Graduate School of Medicine, Japan

Abstract | Poster

Increased levels of APOBEC3 and interferon mRNA in PBMC of Highly Exposed Seronegatives Individuals (HESN)
Joel Armando Vázquez Perez, Instituto Nacional de Enfermedades Respiratorias, Mexico

Abstract

A20 - IFN-I (viral inhibition, immunomodulatory functions)

Characterization of HIV-1 Gag and Nef T cell Responses in an HIV-1 infected Kenyan Population
Robert Langat, University of Nairobi, Kenya

Abstract

A21- NK cells and dendritic cells

Analysis of NK cell receptor-ligand expression in the prevention of AIDS-defining opportunistic infections in patients with low CD4+ T cell count
Francesco Marras, Giannina Gaslini Institute, Italy

Abstract | Poster

DC infected by the ANRS MVAHIV vaccine candidate primes NK cells with anti-HIV specific activity through a mechanism involving NKG2D and NKp46 on NK cells, and membrane-bound IL-15 on DC
Uriel Y. Moreno Nieves, Institut Pasteur, France

Abstract | Poster

A22 - Monocytes and macrophages

HIV-1 stimulates Human Monocytes to produce BAFF through Type I IFN and its secretion level shows sex-related differences
Alejandro Martin Gomez, Université Laval, Canada

Abstract | Poster

HIV-1 virion accumulation and ATP-Induced release in human primary monocyte-derived macrophages
Francesca Graziano, San Raffaele Scientific Institute & San Raffaele University, Italy

Abstract | Poster

A24 - Antibody diversity and function

Generation and characterization of neutralizing anti-V3 scFvs against HIV-1 clade C
Rajesh Kumar, All India Insitute of Medical Sciences, India

Abstract

Antibody and T cell response to the protease cleavage sites drive extensive mutations and correlated with protection against higher dose of SIVmac239 challenge and disease progression in Cynomolgus macaques
Ma Luo, National Microbiology Laboratory & University of Manitoba, Canada

Abstract

A27 - Cellular immunity

Assessing the Role of Antigen-Specific CD8+ T cells in Delayed Progression to AIDS
Melissa Herman, University of Manitoba, Canada

Abstract

HIV-1 Env-specific conformational ADCC epitopes: potential utility for HIV vaccine design
Vijaya Madhavi, University of Melbourne, Australia

Abstract

HIV-1 infection reduces emigration of mature thymocytes from the human thymus by downregulation of the sphingosine-1-kinase receptor S1PR1
Rachel S. Resop, AIDS Institute at UCLA, United States

Abstract

A28 - Mucosal immunity

Severe depletion and exhaustion of mucosal-associated invariant T (MAIT) cells in HIV-1 infected patients
Jan van Lunzen, University Medical Center Hamburg-Eppendorf, Germany

Abstract

A29 - Viral determinants of pathogenesis

NEF-mediated down-regulation of MHC I expression in thymocytes may affect the pathogenicity of a pediatric isolate of X4 HIV-1
Robert Furler, UCLA AIDS Institute & Edison State College, United States

Abstract | Poster

A30 - Acute and early HIV/SIV infection

Analysis of HLA-restricted HIV-specific CD8 T cell responses and viral adaptation in patients with acute HIV infection prior to full seroconversion
Niamh Keane, Murdoch University, Australia

Abstract

A41 - Elite controllers

An elite controller in pregnancy - towards a definition of recovery, though not cure?
Sophia Archuleta, National University of Singapore, Singapore

Abstract | Poster

HIV-1 Vif- and Nef-responses in controllers present higher magnitude and target more conserved, less promiscuous epitopes than responses seen in typical progressors
Leandro Tarosso, University of Sao Paulo, Brazil

Abstract

A44 - Highly exposed seronegative individuals (HESN)

Polymorphisms in the IRF1 gene assoc iated with reduced HIV susceptibility and their impact on plasma and cervical lavage cytokine/chemokine expression
Aida Sivro, University of Manitoba, Canada

Abstract

A45 - Correlates of protection

Functional cure after long term HAART initiated during early HIV infection - a comprehensive case study
Jan van Lunzen, University Medical Center Hamburg-Eppendorf, Germany

Abstract | Poster

A46 - HIV drug development

Evaluation of a panel of selective inhibitors of PKCθ or Lck for controlling HIV-1 replication in CD4+ T cells
Maria Teresa Coiras, Insituto de Salud Carlos III, Spain

Abstract

Safety and Efficacy study of a herbal concoction used for alternative/complementary treatment of HIV infection in Nigeria
Ojezele Matthew Obaineh, Lead City University & Igbinedion University, Nigeria

Abstract | Poster

A47 - Mechanisms of anti-retroviral drug resistance

The real cause of increasing HIV opportunistic infections in CHUK (Kigali University Teaching Hospital)
Dominique Savio Habimana, Rwanda Medical Association, Rwanda

Abstract

Secondary resistance mutations in the R263K integrase inhibitor resistance pathway
Thibault Mesplède, McGill Universtiy AIDS Centre, Canada

Abstract

A49 - Nucleic acid based HIV and SIV therapy development

Characterization of a new use for acyclovir and tenofovir using human cervico-vaginal tissue ex vivo
Christophe Vanpouille, NIH/NIHCD, United States

Abstract

A50 - Design of approaches targeting inflammation/immune activation

Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals
Jan van Lunzen, University Medical Center Hamburg-Eppendorf, Germany

Abstract | Poster

A51 - HIV-hepatitis virus interactions

Hepatitis B virus coinfections: Prevalence and CD4 profile among patients on comprehensive care services in Kenya
Joseph Mwangi, Kenya Medical Research Institute & Jomo Kenyatta University, Kenya

Abstract

A52 - Tuberculosis and other mycobacteria

Anti-mycobacterial activity is enhanced by blocking the Tim3-Galectin 9 interaction in HIV patients
Maria Isabel Sada-Ovalle, Insituto Nacional de Enfermedades Respiratorias, Mexico

Abstract

B56 - Therapeutic vaccine and immune based therapy trials

cART reduces antibody-dependent cellular cytotoxicity to HIV: Implications for Therapeutic Vaccines (Late Breaker)
Vijaya Madhavi, University of Melbourne, Australia

Abstract

B58 - 5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection

5-drug HAART during Primary HIV Infection Leads to a Reduction of Proviral DNA Levels in Comparison to Levels Achievable during Chronic Infection
Eva Wolf, MUC Research, Germany

Abstract | Poster

D24 - Impact of financial crises on the HIV funding and response

Building the Path to the End of AIDS: How investments in HIV prevention research and development responded to the global economic downturn, new research results and funding trends 2000-2012
Mitchell Warren, AVAC, United States

Abstract

Photo gallery